Maryland Capital Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Maryland Capital Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$115	Buy	+2	New	+$110	﹤0.01%	641

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Maryland Capital Advisors's BMRN Position: Q2 2026 in Review

Maryland Capital Advisors opened a new position in BioMarin Pharmaceuticals (BMRN) in Q2 2026: 2 shares worth $115. The stake represents ﹤0.01% of the portfolio and ranks #641 among its holdings.

561 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Maryland Capital Advisors held 2 shares of BioMarin Pharmaceuticals worth $115 as of Q2 2026.
BioMarin Pharmaceuticals was a new Maryland Capital Advisors position in Q2 2026.
BioMarin Pharmaceuticals made up ﹤0.01% of Maryland Capital Advisors's portfolio in Q2 2026, its #641 holding.
561 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Maryland Capital Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.